(NASDAQ: SPRO) Spero Therapeutics's forecast annual revenue growth rate of -31.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Spero Therapeutics's revenue in 2024 is $103,781,000.On average, 1 Wall Street analysts forecast SPRO's revenue for 2024 to be $2,650,361,639, with the lowest SPRO revenue forecast at $2,650,361,639, and the highest SPRO revenue forecast at $2,650,361,639.
In 2025, SPRO is forecast to generate $2,585,718,672 in revenue, with the lowest revenue forecast at $2,585,718,672 and the highest revenue forecast at $2,585,718,672.